| Primary information |
|---|
| ID | antitb_1150 |
| Peptide Name | Nisin V |
| Sequence | I-(Dhb)-AI-(Dha)-LA-(Abu)-PGAK-(Abu)-GALMGANVK-(Abu)-A-(Abu)-ANASIHV-(Dha)-K |
| N-terminal Modification | Free |
| C-terminal Modification | Free |
| Chemical Modification | Dha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and Ala |
| Linear/ Cyclic | Cyclic (5 hinge region dur to presence of lanthion |
| Length | 34 |
| Chirality | L |
| Nature | NA |
| Source | Natural |
| Origin | Produced by Lactococcus lactis |
| Species | Mycobacterium tuberculosis |
| Strain | Mycobacterium tuberculosis H37Ra |
| Inhibition Concentartion | 10% decrease in relative growth as compared to Nicin A |
| In vitro/In vivo | In vitro |
| Cell Line | None |
| Inhibition Concentartion | NA |
| Cytotoxicity | NA |
| In vivo Model | None |
| Lethal Dose | NA |
| Immune Response | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | None |
| Other Activities | Antibacterial (Shigella, Pseudomonas and Salmonella, S. aureus, S. agalactiae and L. monocytogenes) |
| Pubmed ID | 21468208 |
| Year of Publication | 2010 |
| 3-D Structure | NA |